Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Key Insights Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable ...

Beam Therapeutics Inc.’s BEAM share price has surged by 5.12%, which has investors questioning if this is right time to sell.

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Franklin Resources Inc. lifted its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 42.0% during the fourth quarter, Holdings Channel.com reports.The firm owned 21,353 ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports ...

Beam Therapeutics specializes in developing base-edited therapies for rare diseases and cancers. The company’s proprietary base editing platform allows for precise genetic modifications without ...

Get the next trade alert free. Beam Therapeutics Inc. BEAM on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD ...

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.